BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ricklin D, Lambris JD. Complement therapeutics. Semin Immunol 2016;28:205-7. [PMID: 27522923 DOI: 10.1016/j.smim.2016.07.001] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
Number Citing Articles
1 Mödinger Y, Löffler B, Huber-lang M, Ignatius A. Complement involvement in bone homeostasis and bone disorders. Seminars in Immunology 2018;37:53-65. [DOI: 10.1016/j.smim.2018.01.001] [Cited by in Crossref: 33] [Cited by in F6Publishing: 35] [Article Influence: 8.3] [Reference Citation Analysis]
2 Kumar V. The complement system, toll-like receptors and inflammasomes in host defense: three musketeers’ one target: The CS, TLRs, and Inflammasomes are the first line of immune defense working by crosstalking with each other to mount the effective immune response. International Reviews of Immunology 2019;38:131-56. [DOI: 10.1080/08830185.2019.1609962] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 5.3] [Reference Citation Analysis]
3 Mastellos DC, Reis ES, Yancopoulou D, Risitano AM, Lambris JD. Expanding Complement Therapeutics for the Treatment of Paroxysmal Nocturnal Hemoglobinuria. Semin Hematol 2018;55:167-75. [PMID: 30032754 DOI: 10.1053/j.seminhematol.2018.02.002] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 4.5] [Reference Citation Analysis]
4 Gembillo G, Siligato R, Cernaro V, Santoro D. Complement Inhibition Therapy and Dialytic Strategies in Paroxysmal Nocturnal Hemoglobinuria: The Nephrologist's Opinion. J Clin Med 2020;9:E1261. [PMID: 32357555 DOI: 10.3390/jcm9051261] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
5 Mödinger Y, Teixeira GQ, Neidlinger-Wilke C, Ignatius A. Role of the Complement System in the Response to Orthopedic Biomaterials. Int J Mol Sci 2018;19:E3367. [PMID: 30373272 DOI: 10.3390/ijms19113367] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 5.0] [Reference Citation Analysis]
6 Franzin R, Stasi A, Fiorentino M, Simone S, Oberbauer R, Castellano G, Gesualdo L. Renal Delivery of Pharmacologic Agents During Machine Perfusion to Prevent Ischaemia-Reperfusion Injury: From Murine Model to Clinical Trials. Front Immunol 2021;12:673562. [PMID: 34295329 DOI: 10.3389/fimmu.2021.673562] [Reference Citation Analysis]
7 Qin S, Dong N, Yang M, Wang J, Feng X, Wang Y. Complement Inhibitors in Age-Related Macular Degeneration: A Potential Therapeutic Option. J Immunol Res 2021;2021:9945725. [PMID: 34368372 DOI: 10.1155/2021/9945725] [Reference Citation Analysis]
8 Stadlbauer K, Andorfer P, Stadlmayr G, Rüker F, Wozniak-knopp G. Bispecific mAb2 Antibodies Targeting CD59 Enhance the Complement-Dependent Cytotoxicity Mediated by Rituximab. IJMS 2022;23:5208. [DOI: 10.3390/ijms23095208] [Reference Citation Analysis]
9 Ricklin D, Barratt-Due A, Mollnes TE. Complement in clinical medicine: Clinical trials, case reports and therapy monitoring. Mol Immunol 2017;89:10-21. [PMID: 28576323 DOI: 10.1016/j.molimm.2017.05.013] [Cited by in Crossref: 55] [Cited by in F6Publishing: 51] [Article Influence: 11.0] [Reference Citation Analysis]
10 Mastellos DC, Ricklin D, Lambris JD. Clinical promise of next-generation complement therapeutics. Nat Rev Drug Discov 2019;18:707-29. [PMID: 31324874 DOI: 10.1038/s41573-019-0031-6] [Cited by in Crossref: 99] [Cited by in F6Publishing: 93] [Article Influence: 33.0] [Reference Citation Analysis]
11 Reis ES, Mastellos DC, Ricklin D, Mantovani A, Lambris JD. Complement in cancer: untangling an intricate relationship. Nat Rev Immunol 2018;18:5-18. [PMID: 28920587 DOI: 10.1038/nri.2017.97] [Cited by in Crossref: 157] [Cited by in F6Publishing: 155] [Article Influence: 31.4] [Reference Citation Analysis]